Aerie Pharmaceuticals Inc

+0.08 (+1.07%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)361.37M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$31.98 Million
Adjusted EPS-$0.67
See more estimates
10-Day MA$7.71
50-Day MA$9.29
200-Day MA$13.72
See more pivots

Aerie Pharmaceuticals Inc Stock, NASDAQ:AERI

4301 Emperor Boulevard, Suite 400, Durham, North Carolina 27703
United States of America
Phone: +1.919.237.5300
Number of Employees: 365


Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.